Effect of COVID-19 Pandemic-Related Delays in Chemoembolization on the Survival of Patients with Hepatocellular Carcinoma
- PMID: 37090102
- PMCID: PMC10121341
- DOI: 10.1155/2023/8114732
Effect of COVID-19 Pandemic-Related Delays in Chemoembolization on the Survival of Patients with Hepatocellular Carcinoma
Abstract
Background and aims: COVID-19 has led to potential delays in liver cancer treatment, which may have undesirable effects on the prognosis of patients. We aimed to quantify the COVID-19 pandemic impact on the survival of patients with hepatocellular carcinoma (HCC) who underwent transarterial chemoembolization (TACE).
Methods: A retrospective study was conducted in patients with HCC who underwent TACE at a tertiary care center during the prelockdown (March to July 2019) and lockdown (March to July 2020) periods. Demographic data, tumor characteristics, functional status, and vital status were collected from the hospital medical records. The endpoints were TACE interval, treatment response, and survival after TACE. Cox proportional hazards regression determined the significant preoperative factors influencing survival.
Results: Compared to prelockdown, a significant delay occurred during the lockdown in repeated TACE treatments (76.7 vs. 63.5 days, P=0.007). The trend suggested a significant decrease in patients with HCC in the repeated TACE group (-33.3%). After screening, 145 patients were included (prelockdown (n = 87), lockdown (n = 58)). There was no significant difference in the 1-month objective response rate between the prelockdown and lockdown groups (65.5% vs. 64.4%, P=1.00). During follow-up, 56 (64.4%) and 34 (58.6%) deaths occurred in the prelockdown and lockdown groups, respectively (P=0.600). Multivariate analysis revealed no association between the lockdown group and decreased survival (HR 0.88, 95% CI 0.57-1.35, P=0.555).
Conclusions: The impact of the COVID-19 pandemic on liver cancer care resulted in significant decreases and delays in repeated TACE treatments in 2020 compared to 2019. However, treatment delays did not seem to significantly impact survival.
Copyright © 2023 Kittipitch Bannangkoon et al.
Conflict of interest statement
All authors declare that they have no conflicts of interest.
Figures


Similar articles
-
Impact of the COVID-19 Pandemic on the Outcomes of Transarterial Chemoembolization in Patients with Hepatocellular Carcinoma: A Single Center Experience from a Developing Country.Medicina (Kaunas). 2022 Nov 22;58(12):1701. doi: 10.3390/medicina58121701. Medicina (Kaunas). 2022. PMID: 36556903 Free PMC article.
-
The safety and efficacy of transarterial chemoembolization combined with sorafenib and sorafenib mono-therapy in patients with BCLC stage B/C hepatocellular carcinoma.BMC Cancer. 2017 Sep 12;17(1):645. doi: 10.1186/s12885-017-3545-5. BMC Cancer. 2017. PMID: 28899349 Free PMC article.
-
Comparison of hepatic resection and transarterial chemoembolization for solitary hepatocellular carcinoma.World J Gastroenterol. 2015 Apr 21;21(15):4635-43. doi: 10.3748/wjg.v21.i15.4635. World J Gastroenterol. 2015. PMID: 25914473 Free PMC article.
-
Transarterial chemoembolization versus hepatic resection in hepatocellular carcinoma treatment: a meta-analysis.Drug Des Devel Ther. 2015 Aug 10;9:4431-40. doi: 10.2147/DDDT.S86629. eCollection 2015. Drug Des Devel Ther. 2015. PMID: 26309396 Free PMC article. Review.
-
Adjuvant transarterial chemoembolization after curative hepatectomy for hepatocellular carcinoma with microvascular invasion: A systematic review and meta-analysis.Clin Res Hepatol Gastroenterol. 2020 Apr;44(2):142-154. doi: 10.1016/j.clinre.2019.06.012. Epub 2019 Jul 11. Clin Res Hepatol Gastroenterol. 2020. PMID: 31303533
References
-
- World Health Organization. Coronavirus Disease (COVID-19) Weekly Epidemiological Update and Weekly Operational Update . Geneva, Switzerland: World Health Organization; 2022. https://www.who.int/emergencies/diseases/novel-coronavirus-2019/situatio... .
-
- World Health Organization. Coronavirus Disease (COVID-19): WHO’s Action in Countries . Geneva, Switzerland: World Health Organization; 2020. https://www.who.int/docs/default-source/coronaviruse/country-case-studie... .
-
- World Health Organization. COVID-19 Significantly Impacts Health Services for Noncommunicable Diseases . Geneva, Switzerland: World Health Organization; 2020. https://www.who.int/news/item/01-06-2020-covid-19-significantlyimpacts-h... .
MeSH terms
LinkOut - more resources
Full Text Sources
Medical
Miscellaneous